The Trade

We trimmed LRMR in December 2025 on going concern risk. That risk is gone. The stock is at $4.47, below the $5.00 offering price where the board collectively put $25.5 million of their own money three weeks ago. BLA submission is three months away.

The market is pricing a 24-42% probability of approval. We think it's 75-80%. The question for IC is whether to add back the trimmed shares before the catalyst window closes.

15 for 15

Start with the base rate. Lysosomal storage enzyme replacement therapies submitted as BLAs have been approved 15 out of 15 times. Every single one. 100%. Nomlabofusp is a frataxin replacement protein for Friedreich's ataxia — a rare, progressive neurological disease with one approved drug (Biogen's SKYCLARYS) that treats symptoms, not the root cause. Nomlabofusp would be the first drug to address the underlying frataxin deficiency.

Breakthrough Therapy Designation approval rates run approximately 90% across all indications. LRMR has BTD.

The FDA has aligned with LRMR on every major regulatory checkpoint: agreed on skin frataxin as a novel surrogate endpoint for accelerated approval, confirmed the exposure-response analysis approach, offered to pre-review the statistical plan for the FACOMS natural history comparison, concurred on the potency control strategy, and selected nomlabofusp for the START pilot program. That's an unusually detailed level of alignment for any program, rare disease or not. Every checkpoint green-lit except one.

Then the competitor died. PTC Therapeutics received a Complete Response Letter in August 2025 — FDA said "substantial evidence of efficacy was not demonstrated" for vatiquinone. In December 2025, FDA told PTC in a Type C meeting that resubmission would require an additional study, and that it "could be an open label study with a natural history control group." That is exactly LRMR's approach. PTC hasn't even designed its resubmission study yet. They're 2-3 years behind, minimum. The gene therapy competitors (Lexeo, Voyager, Solid Biosciences) are 4-5 years from approval. Nomlabofusp is the most advanced FA program in the US pipeline, and it's not close.

Back out the implied probability from the stock price:

Under every reasonable construction, the market prices approval below 42%. The base rate says 100%. The BTD rate says 90%. Eleven of eleven analysts say Buy, mean target $16.60. Either we're wrong about one specific thing, or the market is applying a generic small-cap biotech discount to a program with primary-source evidence of non-generic regulatory alignment.

The One Number That Matters

10.8%.

Seven of 65 patients experienced anaphylaxis in the first six weeks of dosing. All events resolved with standard treatment. Here's the thing the FDA said about it: safety database adequacy "will be a matter of review at the time of BLA submission." That's the one item they did not green-light. Every other checkpoint — yes. This one — we'll see.

The memo could stop there and say "binary risk, size accordingly." But context matters.

First, 8,000 doses. The 10-K discloses approximately 8,000 total doses administered across the clinical program. Sixty-five patients at 8,000 doses means substantial cumulative exposure at therapeutic levels. The anaphylaxis events were front-loaded — all in the first six weeks — and 14 patients have been on treatment for 6+ months, 8 for 1+ year, with "generally well-tolerated" profiles at steady state. The database is thin on patient count. It is not thin on dosing exposure.

Second, enzyme replacement therapy precedent. Infusion-related reaction rates of 10-30% are standard for the drug class. Myozyme (Pompe disease) saw infusion reactions in roughly half of patients. Cerezyme (Gaucher disease) is well-known for them. These drugs got approved — with REMS, with monitoring protocols, with mandatory observation periods — because the diseases are devastating and the drugs work. FDA doesn't reject ERTs for manageable infusion reactions when there's no alternative root-cause therapy. A REMS with mandatory observation during initial titration is the most likely outcome, not a CRL.

Third, the company implemented a titration protocol specifically to address early anaphylaxis: 5mg initial dose, then 25mg an hour later under observation, then 25mg daily for 30 days before escalating to 50mg. This is exactly the kind of mitigation FDA expects to see in a BLA safety package.

Fourth, what "will be a matter of review" actually means procedurally. FDA didn't say the database is inadequate. They said they'd evaluate it at submission. For a BTD program with a novel surrogate endpoint in a rare disease, this is standard language — FDA doesn't pre-commit on safety database adequacy before seeing the full BLA package. Reading this as a red flag requires reading the absence of a green light as a yellow one. That's reasonable caution. It's not the same as evidence of a problem.

The honest position: the anaphylaxis rate is manageable by ERT precedent, the dosing exposure is substantial, and the mitigation protocol is in place. But the patient count is genuinely small at 65, and we cannot verify from the outside what FDA will decide when they review the full package. This is the residual uncertainty in the thesis. It's real, but it doesn't override the base rate.

Flynn's $55 Million

James Flynn, a director, purchased $30 million of LRMR stock at $3.20 in July 2025, then another $25 million at $5.00 in February 2026. Thomas Hamilton put in $500,000. Sherman and Thomas bought $25,000 each. The entire board participated in the offering.

What does Flynn see? Not unblinded data — directors on public company boards typically don't have access to individual patient-level safety data from ongoing studies. What they do have is board-level visibility into FDA interaction dynamics, safety monitoring committee reports, BLA preparation progress, and the tenor of regulatory discussions. Flynn has seen whatever the safety monitoring committee has flagged (or not flagged) and whatever the FDA has communicated in pre-BLA interactions. He put $55 million in across two tranches at increasing prices.

We should be honest about the limits of this signal. We don't know what specifically Flynn based his conviction on. What we do know is: a person with more information than the market put $55 million at risk at prices above where the stock currently trades, and he did it after the anaphylaxis data was known. That's not proof. It's corroboration — the strongest non-regulatory corroboration available.

The stock is at $4.47. You can buy shares below where a director with $55 million of conviction entered three weeks ago.

The Catalyst Chain

Three catalysts, each reducing uncertainty:

Q2 2026 (2-3 months): Open-label topline data. If the safety profile under the new titration protocol is clean, the stock reprices to $6-8 as approval probability increases. If new safety signals emerge, it drops to $2.50-3.50.

June 2026 (3 months): BLA submission. Confirms execution, starts the FDA clock. PPQ is "nearing completion." One outstanding item: Lonza comparability data for commercial-scale material needs FDA review. This is standard for any manufacturing scale-up but is a BLA readiness risk worth noting.

~December 2026 (9 months): PDUFA if Priority Review. BTD strongly suggests Priority Review (6-month clock). Approval gaps the stock to $14-20. CRL gaps it to $1-3. Standard Review would push to ~June 2027, tight against the Q2 2027 cash runway but survivable with $244.5 million in combined liquidity and post-PPQ burn normalization.

The setup compounds. Each positive catalyst reprices the stock upward before the binary PDUFA event.

The Decision

We trimmed 50% in December 2025 because LRMR was running out of money. The 10-K just filed shows that risk is resolved: $244.5 million in combined liquidity, runway to Q2 2027, no going concern language. The reason we sold is gone.

Holding a trimmed position for a reason that no longer exists is not discipline — it's inertia.

The risk is real: 10.8% anaphylaxis, 65 patients, FDA hasn't pre-approved the safety database. But the ERT base rate says manageable infusion reactions don't block approval when the drug works and the disease is devastating. The primary source regulatory record — 15/15 BLA base rate, BTD, surrogate agreement, pre-review offer, potency concurrence, competitor CRL validating the methodology — is stronger than any single bear argument against it.

The case for adding back: Current levels ($4.00-4.50) are below where a director with $55 million of conviction entered three weeks ago. The trimmed position can be rebuilt at a discount to the offering price — sized for survival, affordable to be wrong — while capturing the pre-catalyst edge before Q2 2026 OL data and June 2026 BLA submission.

Appendix: Factor Decomposition

94% idiosyncratic variance. Market beta explains almost nothing. This is a pure binary biotech — the variance IS the approval outcome.

Edge = 75% of thesis. Right at the Paleologo threshold.

Appendix: Scenario-Weighted EV

Alpha: 123% annualized base case. 36% under triple haircut (lower target, lower conviction, lower edge). Positive across every stress test.

Evidence